The short answer
Echinacea may affect drug-metabolizing enzymes, but its effect on acalabrutinib exposure or effectiveness is not established. Have the exact preparation reviewed and keep the capsule or tablet instructions for your prescribed product.
What this answer covers
Echinacea purpurea preparations with oral acalabrutinib, distinguishing free-base capsules, maleate tablets and active ACP-5862.
- Supplement or preparation
- Echinacea purpurea
- Medication ingredient
- acalabrutinib
Keep capsule and tablet directions separate
CALQUENCE capsules contain acalabrutinib, while the tablets use its maleate salt. Their acid-reducer directions differ: the tablet formulation was designed to allow use with proton-pump inhibitors. This formulation difference does not prove an echinacea interaction, and you should not switch products yourself.
Human echinacea findings differ by experiment
One study found a modest decrease in oral midazolam exposure after echinacea, while a boosted antiviral regimen was unchanged. Another study found opposing intestinal and hepatic CYP3A effects, with no significant change in oral midazolam clearance. These findings do not establish that echinacea is a strong inducer.
An active metabolite complicates the prediction
Acalabrutinib forms the active metabolite ACP-5862. Drug-interaction research considered both compounds, because a change in the parent drug alone does not necessarily describe the same change in total active exposure. No study here measured both during echinacea use.
Review the complete supplement
Show the team the echinacea species, plant part, extract and dose, including blends. No validated spacing interval or automatic acalabrutinib dose change was established. Continue the prescribed formulation and monitoring plan rather than acting on another probe drug’s result.
Evidence and practical considerations
Absorption & effectiveness
Mixed human probe effects do not establish a uniform reduction in acalabrutinib or total active exposure.
- Exact scope
- Echinacea purpurea preparations with oral acalabrutinib, distinguishing free-base capsules, maleate tablets and active ACP-5862. with RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact acalabrutinib-echinacea clinical PK or response study. Modest/mixed other-drug findings cannot establish strong induction or reduced active-moiety exposure.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding/low platelet warnings; CYP3A induction may lower exposure; maleate-tablet PPI null differs from capsule restriction.
How this applies: RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed capsules.
Capsules have acid-reducer restrictions distinct from maleate tablets.
How this applies: Same IN with explicit formulation boundary.
Do not transfer capsule pH guidance to maleate tablet or reverse.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Clinical PK data and verified PBPK model.
Parent and active-metabolite changes differ; model addresses total active exposure.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Full original model body; predicted and measured components distinguished, no botanical co-use.
Source 4: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Three healthy-volunteer studies.
Tablet and capsule exposures comparable; PPI did not impair tablet total exposure or BTK occupancy.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Abstract-only specific formulations; cannot transfer to all compounded preparations or assume every PK parameter unchanged.
Source 5: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 13 healthy volunteers.
Midazolam AUC fell 27%; lopinavir/ritonavir exposure did not significantly change.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Original HTML body read after XML404. Other-drug study, modest probe induction, not strong-inducer classification or measured acalabrutinib response.
Source 6: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 12 healthy volunteers.
Hepatic and intestinal CYP3A effects differed; oral midazolam clearance was not significantly altered.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Abstract-only; exact preparation and extraction-site dependence preclude a uniform target-drug direction.
Source 7: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
acalabrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 022562719e179878
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.